Clinical trial

A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy…

NCT00002086 · Glaxo Wellcome, Industry · Completed

Key facts

NCT number NCT00002086
Title A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
Official title A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
Lead sponsor Glaxo Wellcome, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Zidovudine, Zalcitabine, Interferon alfa-n1
Enrollment 256
First posted Aug 31, 2001
Last update posted Jun 24, 2005
Countries United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies